APO Research
Talk to an analyst

APO RESEARCH · REPORT

Tenofovir Disoproxil Fumarate Tablets

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Tenofovir Disoproxil Fumarate Tablets Market Outlook and Growth Opportunities 2026

29 December 2025207 pages

Choose your research edition.

Industry ResearchTenofovir Disoproxil Fumarate Tablets Industry Research Report 2026135 pages · $2,950 USDIndustry Growth & TrendsGlobal Tenofovir Disoproxil Fumarate Tablets Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Tenofovir Disoproxil Fumarate Tablets Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Tenofovir Disoproxil Fumarate Tablets Market Outlook and Growth Opportunities 2026207 pages · $4,250 USDMarket Analysis & ForecastGlobal Tenofovir Disoproxil Fumarate Tablets Market Analysis and Forecast 2026-2032206 pages · $4,950 USD

Market perspective

The global Tenofovir Disoproxil Fumarate Tablets market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Tenofovir Disoproxil Fumarate Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Tenofovir Disoproxil Fumarate Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Tenofovir Disoproxil Fumarate Tablets is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Tenofovir Disoproxil Fumarate Tablets market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Tenofovir Disoproxil Fumarate Tablets market include Aurobindo Pharma, Gilead Sciences, GSK, Hetero Drugs, Strides Pharma, Teva Pharmaceuticals, Chengdu Beite Pharmaceutical, Haisco Pharmaceutical and Shijiazhuang Lonzeal Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Tenofovir Disoproxil Fumarate Tablets market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Tenofovir Disoproxil Fumarate Tablets and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Tenofovir Disoproxil Fumarate Tablets sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Tenofovir Disoproxil Fumarate Tablets market size, projected growth trends, production technologies, key applications, and end-use industries.

Tenofovir Disoproxil Fumarate Tablets Segment by Company

Aurobindo Pharma

Gilead Sciences

GSK

Hetero Drugs

Strides Pharma

Teva Pharmaceuticals

Chengdu Beite Pharmaceutical

Haisco Pharmaceutical

Shijiazhuang Lonzeal Pharmaceuticals

Luoxin Pharmaceuticals

Qilu Pharmaceutical

Shanghai Haini Pharmaceutical

Beijing SL Pharmaceutical

Sichuan Kelun Pharmaceutical

Chongqing Yaoyou Pharmaceutical

Zhejiang Sukean Pharmaceutical

Chia Tai Tianqing Pharmaceutical

Tenofovir Disoproxil Fumarate Tablets Segment by Type

Original Drug

Generic Drug

Tenofovir Disoproxil Fumarate Tablets Segment by Application

HIV-1 Infection

Chronic Hepatitis B

Tenofovir Disoproxil Fumarate Tablets Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Tenofovir Disoproxil Fumarate Tablets status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Tenofovir Disoproxil Fumarate Tablets market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Tenofovir Disoproxil Fumarate Tablets significant trends, drivers, influence factors in global and regions.

6. To analyze Tenofovir Disoproxil Fumarate Tablets competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tenofovir Disoproxil Fumarate Tablets market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Tenofovir Disoproxil Fumarate Tablets and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tenofovir Disoproxil Fumarate Tablets.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Tenofovir Disoproxil Fumarate Tablets market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Tenofovir Disoproxil Fumarate Tablets industry.

Chapter 3: Detailed analysis of Tenofovir Disoproxil Fumarate Tablets manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Tenofovir Disoproxil Fumarate Tablets in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Tenofovir Disoproxil Fumarate Tablets in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Tenofovir Disoproxil Fumarate Tablets Industry Trends Table 2. Tenofovir Disoproxil Fumarate Tablets Industry Drivers Table 3. Tenofovir Disoproxil Fumarate Tablets Industry Opportunities and Challenges Table 4. Tenofovir Disoproxil Fumarate Tablets Industry Restraints Table 5. Global Tenofovir Disoproxil Fumarate Tablets Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Tenofovir Disoproxil Fumarate Tablets Revenue Share by Company (2021-2026) Table 7. Global Tenofovir Disoproxil Fumarate Tablets Sales Volume by Company (K Units) & (2021-2026) Table 8. Global Tenofovir Disoproxil Fumarate Tablets Sales Volume Share by Company (2021-2026) Table 9. Global Tenofovir Disoproxil Fumarate Tablets Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Tenofovir Disoproxil Fumarate Tablets Company Ranking, (2024-2026) & (USD Million) Table 11. Global Tenofovir Disoproxil Fumarate Tablets Key Company Manufacturing Base & Headquarters Table 12. Global Tenofovir Disoproxil Fumarate Tablets Company, Product Type & Application Table 13. Global Tenofovir Disoproxil Fumarate Tablets Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Tenofovir Disoproxil Fumarate Tablets by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Original Drug Table 18. Significant Companies of Generic Drug Table 19. Global Tenofovir Disoproxil Fumarate Tablets Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global Tenofovir Disoproxil Fumarate Tablets Sales Volume by Type (2021-2026) & (K Units) Table 21. Global Tenofovir Disoproxil Fumarate Tablets Sales Volume by Type (2027-2032) & (K Units) Table 22. Global Tenofovir Disoproxil Fumarate Tablets Sales Volume Share by Type (2021-2026) Table 23. Global Tenofovir Disoproxil Fumarate Tablets Sales Volume Share by Type (2027-2032) Table 24. Global Tenofovir Disoproxil Fumarate Tablets Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Tenofovir Disoproxil Fumarate Tablets Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Tenofovir Disoproxil Fumarate Tablets Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Type (2021-2026) Table 28. Global Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Type (2027-2032) Table 29. Significant Companies of HIV-1 Infection Table 30. Significant Companies of Chronic Hepatitis B Table 31. Global Tenofovir Disoproxil Fumarate Tablets Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Tenofovir Disoproxil Fumarate Tablets Sales Volume by Application (2021-2026) & (K Units) Table 33. Global Tenofovir Disoproxil Fumarate Tablets Sales Volume by Application (2027-2032) & (K Units) Table 34. Global Tenofovir Disoproxil Fumarate Tablets Sales Volume Share by Application (2021-2026) Table 35. Global Tenofovir Disoproxil Fumarate Tablets Sales Volume Share by Application (2027-2032) Table 36. Global Tenofovir Disoproxil Fumarate Tablets Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Tenofovir Disoproxil Fumarate Tablets Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Tenofovir Disoproxil Fumarate Tablets Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Application (2021-2026) Table 40. Global Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Application (2027-2032) Table 41. Global Tenofovir Disoproxil Fumarate Tablets Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Tenofovir Disoproxil Fumarate Tablets Sales by Region (2021-2026) & (K Units) Table 43. Global Tenofovir Disoproxil Fumarate Tablets Sales Market Share by Region (2021-2026) Table 44. Global Tenofovir Disoproxil Fumarate Tablets Sales by Region (2027-2032) & (K Units) Table 45. Global Tenofovir Disoproxil Fumarate Tablets Sales Market Share by Region (2027-2032) Table 46. Global Tenofovir Disoproxil Fumarate Tablets Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Tenofovir Disoproxil Fumarate Tablets Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Region (2021-2026) Table 49. Global Tenofovir Disoproxil Fumarate Tablets Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Region (2027-2032) Table 51. Global Tenofovir Disoproxil Fumarate Tablets Market Average Price (US$/Unit) by Region (2021-2026) Table 52. Global Tenofovir Disoproxil Fumarate Tablets Market Average Price (US$/Unit) by Region (2027-2032) Table 53. Global Tenofovir Disoproxil Fumarate Tablets Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 54. Global Tenofovir Disoproxil Fumarate Tablets Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Tenofovir Disoproxil Fumarate Tablets Sales by Country (2021-2026) & (K Units) Table 56. Global Tenofovir Disoproxil Fumarate Tablets Sales Market Share by Country (2021-2026) Table 57. Global Tenofovir Disoproxil Fumarate Tablets Sales by Country (2027-2032) & (K Units) Table 58. Global Tenofovir Disoproxil Fumarate Tablets Sales Market Share by Country (2027-2032) Table 59. Global Tenofovir Disoproxil Fumarate Tablets Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Tenofovir Disoproxil Fumarate Tablets Sales Value Market Share by Country (2021-2026) Table 61. Global Tenofovir Disoproxil Fumarate Tablets Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Tenofovir Disoproxil Fumarate Tablets Sales Value Market Share by Country (2027-2032) Table 63. Aurobindo Pharma Company Information Table 64. Aurobindo Pharma Business Overview Table 65. Aurobindo Pharma Tenofovir Disoproxil Fumarate Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Aurobindo Pharma Tenofovir Disoproxil Fumarate Tablets Product Portfolio Table 67. Aurobindo Pharma Recent Development Table 68. Gilead Sciences Company Information Table 69. Gilead Sciences Business Overview Table 70. Gilead Sciences Tenofovir Disoproxil Fumarate Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Gilead Sciences Tenofovir Disoproxil Fumarate Tablets Product Portfolio Table 72. Gilead Sciences Recent Development Table 73. GSK Company Information Table 74. GSK Business Overview Table 75. GSK Tenofovir Disoproxil Fumarate Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. GSK Tenofovir Disoproxil Fumarate Tablets Product Portfolio Table 77. GSK Recent Development Table 78. Hetero Drugs Company Information Table 79. Hetero Drugs Business Overview Table 80. Hetero Drugs Tenofovir Disoproxil Fumarate Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Hetero Drugs Tenofovir Disoproxil Fumarate Tablets Product Portfolio Table 82. Hetero Drugs Recent Development Table 83. Strides Pharma Company Information Table 84. Strides Pharma Business Overview Table 85. Strides Pharma Tenofovir Disoproxil Fumarate Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. Strides Pharma Tenofovir Disoproxil Fumarate Tablets Product Portfolio Table 87. Strides Pharma Recent Development Table 88. Teva Pharmaceuticals Company Information Table 89. Teva Pharmaceuticals Business Overview Table 90. Teva Pharmaceuticals Tenofovir Disoproxil Fumarate Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. Teva Pharmaceuticals Tenofovir Disoproxil Fumarate Tablets Product Portfolio Table 92. Teva Pharmaceuticals Recent Development Table 93. Chengdu Beite Pharmaceutical Company Information Table 94. Chengdu Beite Pharmaceutical Business Overview Table 95. Chengdu Beite Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Chengdu Beite Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Product Portfolio Table 97. Chengdu Beite Pharmaceutical Recent Development Table 98. Haisco Pharmaceutical Company Information Table 99. Haisco Pharmaceutical Business Overview Table 100. Haisco Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 101. Haisco Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Product Portfolio Table 102. Haisco Pharmaceutical Recent Development Table 103. Shijiazhuang Lonzeal Pharmaceuticals Company Information Table 104. Shijiazhuang Lonzeal Pharmaceuticals Business Overview Table 105. Shijiazhuang Lonzeal Pharmaceuticals Tenofovir Disoproxil Fumarate Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 106. Shijiazhuang Lonzeal Pharmaceuticals Tenofovir Disoproxil Fumarate Tablets Product Portfolio Table 107. Shijiazhuang Lonzeal Pharmaceuticals Recent Development Table 108. Luoxin Pharmaceuticals Company Information Table 109. Luoxin Pharmaceuticals Business Overview Table 110. Luoxin Pharmaceuticals Tenofovir Disoproxil Fumarate Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 111. Luoxin Pharmaceuticals Tenofovir Disoproxil Fumarate Tablets Product Portfolio Table 112. Luoxin Pharmaceuticals Recent Development Table 113. Qilu Pharmaceutical Company Information Table 114. Qilu Pharmaceutical Business Overview Table 115. Qilu Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 116. Qilu Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Product Portfolio Table 117. Qilu Pharmaceutical Recent Development Table 118. Shanghai Haini Pharmaceutical Company Information Table 119. Shanghai Haini Pharmaceutical Business Overview Table 120. Shanghai Haini Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 121. Shanghai Haini Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Product Portfolio Table 122. Shanghai Haini Pharmaceutical Recent Development Table 123. Beijing SL Pharmaceutical Company Information Table 124. Beijing SL Pharmaceutical Business Overview Table 125. Beijing SL Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 126. Beijing SL Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Product Portfolio Table 127. Beijing SL Pharmaceutical Recent Development Table 128. Sichuan Kelun Pharmaceutical Company Information Table 129. Sichuan Kelun Pharmaceutical Business Overview Table 130. Sichuan Kelun Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 131. Sichuan Kelun Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Product Portfolio Table 132. Sichuan Kelun Pharmaceutical Recent Development Table 133. Chongqing Yaoyou Pharmaceutical Company Information Table 134. Chongqing Yaoyou Pharmaceutical Business Overview Table 135. Chongqing Yaoyou Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 136. Chongqing Yaoyou Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Product Portfolio Table 137. Chongqing Yaoyou Pharmaceutical Recent Development Table 138. Zhejiang Sukean Pharmaceutical Company Information Table 139. Zhejiang Sukean Pharmaceutical Business Overview Table 140. Zhejiang Sukean Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 141. Zhejiang Sukean Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Product Portfolio Table 142. Zhejiang Sukean Pharmaceutical Recent Development Table 143. Chia Tai Tianqing Pharmaceutical Company Information Table 144. Chia Tai Tianqing Pharmaceutical Business Overview Table 145. Chia Tai Tianqing Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 146. Chia Tai Tianqing Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Product Portfolio Table 147. Chia Tai Tianqing Pharmaceutical Recent Development Table 148. Key Raw Materials Table 149. Raw Materials Key Suppliers Table 150. Tenofovir Disoproxil Fumarate Tablets Distributors List Table 151. Tenofovir Disoproxil Fumarate Tablets Customers List Table 152. Research Programs/Design for This Report Table 153. Authors List of This Report Table 154. Secondary Sources Table 155. Primary Sources List of Figures Figure 1. Tenofovir Disoproxil Fumarate Tablets Product Image Figure 2. Global Tenofovir Disoproxil Fumarate Tablets Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Tenofovir Disoproxil Fumarate Tablets Sales Value (2021-2032) & (US$ Million) Figure 4. Global Tenofovir Disoproxil Fumarate Tablets Sales (2021-2032) & (K Units) Figure 5. Global Tenofovir Disoproxil Fumarate Tablets Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Tenofovir Disoproxil Fumarate Tablets Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Original Drug Image Figure 10. Generic Drug Image Figure 11. Global Tenofovir Disoproxil Fumarate Tablets Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global Tenofovir Disoproxil Fumarate Tablets Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Tenofovir Disoproxil Fumarate Tablets Sales Volume Share by Type (2021-2032) Figure 14. Global Tenofovir Disoproxil Fumarate Tablets Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Tenofovir Disoproxil Fumarate Tablets Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Type (2021-2032) Figure 17. HIV-1 Infection Image Figure 18. Chronic Hepatitis B Image Figure 19. Global Tenofovir Disoproxil Fumarate Tablets Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Tenofovir Disoproxil Fumarate Tablets Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Tenofovir Disoproxil Fumarate Tablets Sales Volume Share by Application (2021-2032) Figure 22. Global Tenofovir Disoproxil Fumarate Tablets Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Tenofovir Disoproxil Fumarate Tablets Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Application (2021-2032) Figure 25. Global Tenofovir Disoproxil Fumarate Tablets Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 26. Global Tenofovir Disoproxil Fumarate Tablets Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Tenofovir Disoproxil Fumarate Tablets Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Tenofovir Disoproxil Fumarate Tablets Sales Value (2021-2032) & (US$ Million) Figure 30. North America Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Tenofovir Disoproxil Fumarate Tablets Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Tenofovir Disoproxil Fumarate Tablets Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Tenofovir Disoproxil Fumarate Tablets Sales Value (2021-2032) & (US$ Million) Figure 36. South America Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Tenofovir Disoproxil Fumarate Tablets Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Tenofovir Disoproxil Fumarate Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Tenofovir Disoproxil Fumarate Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Tenofovir Disoproxil Fumarate Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Tenofovir Disoproxil Fumarate Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Tenofovir Disoproxil Fumarate Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Tenofovir Disoproxil Fumarate Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Tenofovir Disoproxil Fumarate Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Tenofovir Disoproxil Fumarate Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Tenofovir Disoproxil Fumarate Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Tenofovir Disoproxil Fumarate Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Tenofovir Disoproxil Fumarate Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Tenofovir Disoproxil Fumarate Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Tenofovir Disoproxil Fumarate Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Tenofovir Disoproxil Fumarate Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Tenofovir Disoproxil Fumarate Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Tenofovir Disoproxil Fumarate Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Tenofovir Disoproxil Fumarate Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Tenofovir Disoproxil Fumarate Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Tenofovir Disoproxil Fumarate Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Tenofovir Disoproxil Fumarate Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Tenofovir Disoproxil Fumarate Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Tenofovir Disoproxil Fumarate Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Tenofovir Disoproxil Fumarate Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Tenofovir Disoproxil Fumarate Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Tenofovir Disoproxil Fumarate Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Tenofovir Disoproxil Fumarate Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Tenofovir Disoproxil Fumarate Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Tenofovir Disoproxil Fumarate Tablets Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Tenofovir Disoproxil Fumarate Tablets Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Tenofovir Disoproxil Fumarate Tablets Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • Original Drug
  • Generic Drug
Applications
  • HIV-1 Infection
  • Chronic Hepatitis B
Companies covered
  • Aurobindo Pharma
  • Gilead Sciences
  • GSK
  • Hetero Drugs
  • Strides Pharma
  • Teva Pharmaceuticals
  • Chengdu Beite Pharmaceutical
  • Haisco Pharmaceutical
  • Shijiazhuang Lonzeal Pharmaceuticals
  • Luoxin Pharmaceuticals
  • Qilu Pharmaceutical
  • Shanghai Haini Pharmaceutical
  • Beijing SL Pharmaceutical
  • Sichuan Kelun Pharmaceutical
  • Chongqing Yaoyou Pharmaceutical
  • Zhejiang Sukean Pharmaceutical
  • Chia Tai Tianqing Pharmaceutical

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Tenofovir Disoproxil Fumarate Tablets Sales Value (2021-2032)
  4. 1.2.2 Global Tenofovir Disoproxil Fumarate Tablets Sales Volume (2021-2032)
  5. 1.2.3 Global Tenofovir Disoproxil Fumarate Tablets Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Tenofovir Disoproxil Fumarate Tablets Market Dynamics
  1. 2.1 Tenofovir Disoproxil Fumarate Tablets Industry Trends
  2. 2.2 Tenofovir Disoproxil Fumarate Tablets Industry Drivers
  3. 2.3 Tenofovir Disoproxil Fumarate Tablets Industry Opportunities and Challenges
  4. 2.4 Tenofovir Disoproxil Fumarate Tablets Industry Restraints
3 Tenofovir Disoproxil Fumarate Tablets Market by Company
  1. 3.1 Global Tenofovir Disoproxil Fumarate Tablets Company Revenue Ranking in 2025
  2. 3.2 Global Tenofovir Disoproxil Fumarate Tablets Revenue by Company (2021-2026)
  3. 3.3 Global Tenofovir Disoproxil Fumarate Tablets Sales Volume by Company (2021-2026)
  4. 3.4 Global Tenofovir Disoproxil Fumarate Tablets Average Price by Company (2021-2026)
  5. 3.5 Global Tenofovir Disoproxil Fumarate Tablets Company Ranking (2024-2026)
  6. 3.6 Global Tenofovir Disoproxil Fumarate Tablets Company Manufacturing Base and Headquarters
  7. 3.7 Global Tenofovir Disoproxil Fumarate Tablets Company Product Type and Application
  8. 3.8 Global Tenofovir Disoproxil Fumarate Tablets Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Tenofovir Disoproxil Fumarate Tablets Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Tenofovir Disoproxil Fumarate Tablets Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Tenofovir Disoproxil Fumarate Tablets Market by Type
  1. 4.1 Tenofovir Disoproxil Fumarate Tablets Type Introduction
  2. 4.1.1 Original Drug
  3. 4.1.2 Generic Drug
  4. 4.2 Global Tenofovir Disoproxil Fumarate Tablets Sales Volume by Type
  5. 4.2.1 Global Tenofovir Disoproxil Fumarate Tablets Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Tenofovir Disoproxil Fumarate Tablets Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Tenofovir Disoproxil Fumarate Tablets Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Tenofovir Disoproxil Fumarate Tablets Sales Value by Type
  9. 4.3.1 Global Tenofovir Disoproxil Fumarate Tablets Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Tenofovir Disoproxil Fumarate Tablets Sales Value by Type (2021-2032)
  11. 4.3.3 Global Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Type (2021-2032)
5 Tenofovir Disoproxil Fumarate Tablets Market by Application
  1. 5.1 Tenofovir Disoproxil Fumarate Tablets Application Introduction
  2. 5.1.1 HIV-1 Infection
  3. 5.1.2 Chronic Hepatitis B
  4. 5.2 Global Tenofovir Disoproxil Fumarate Tablets Sales Volume by Application
  5. 5.2.1 Global Tenofovir Disoproxil Fumarate Tablets Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Tenofovir Disoproxil Fumarate Tablets Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Tenofovir Disoproxil Fumarate Tablets Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Tenofovir Disoproxil Fumarate Tablets Sales Value by Application
  9. 5.3.1 Global Tenofovir Disoproxil Fumarate Tablets Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Tenofovir Disoproxil Fumarate Tablets Sales Value by Application (2021-2032)
  11. 5.3.3 Global Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Application (2021-2032)
6 Tenofovir Disoproxil Fumarate Tablets Regional Sales and Value Analysis
  1. 6.1 Global Tenofovir Disoproxil Fumarate Tablets Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Tenofovir Disoproxil Fumarate Tablets Sales by Region (2021-2032)
  3. 6.2.1 Global Tenofovir Disoproxil Fumarate Tablets Sales by Region: 2021-2026
  4. 6.2.2 Global Tenofovir Disoproxil Fumarate Tablets Sales by Region (2027-2032)
  5. 6.3 Global Tenofovir Disoproxil Fumarate Tablets Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Tenofovir Disoproxil Fumarate Tablets Sales Value by Region (2021-2032)
  7. 6.4.1 Global Tenofovir Disoproxil Fumarate Tablets Sales Value by Region: 2021-2026
  8. 6.4.2 Global Tenofovir Disoproxil Fumarate Tablets Sales Value by Region (2027-2032)
  9. 6.5 Global Tenofovir Disoproxil Fumarate Tablets Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Tenofovir Disoproxil Fumarate Tablets Sales Value (2021-2032)
  12. 6.6.2 North America Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Tenofovir Disoproxil Fumarate Tablets Sales Value (2021-2032)
  15. 6.7.2 Europe Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Tenofovir Disoproxil Fumarate Tablets Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Tenofovir Disoproxil Fumarate Tablets Sales Value (2021-2032)
  21. 6.9.2 South America Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Tenofovir Disoproxil Fumarate Tablets Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Country, 2025 VS 2032
7 Tenofovir Disoproxil Fumarate Tablets Country-level Sales and Value Analysis
  1. 7.1 Global Tenofovir Disoproxil Fumarate Tablets Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Tenofovir Disoproxil Fumarate Tablets Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Tenofovir Disoproxil Fumarate Tablets Sales by Country (2021-2032)
  4. 7.3.1 Global Tenofovir Disoproxil Fumarate Tablets Sales by Country (2021-2026)
  5. 7.3.2 Global Tenofovir Disoproxil Fumarate Tablets Sales by Country (2027-2032)
  6. 7.4 Global Tenofovir Disoproxil Fumarate Tablets Sales Value by Country (2021-2032)
  7. 7.4.1 Global Tenofovir Disoproxil Fumarate Tablets Sales Value by Country (2021-2026)
  8. 7.4.2 Global Tenofovir Disoproxil Fumarate Tablets Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Tenofovir Disoproxil Fumarate Tablets Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Tenofovir Disoproxil Fumarate Tablets Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Tenofovir Disoproxil Fumarate Tablets Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Tenofovir Disoproxil Fumarate Tablets Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Tenofovir Disoproxil Fumarate Tablets Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Tenofovir Disoproxil Fumarate Tablets Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Tenofovir Disoproxil Fumarate Tablets Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Tenofovir Disoproxil Fumarate Tablets Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Tenofovir Disoproxil Fumarate Tablets Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Tenofovir Disoproxil Fumarate Tablets Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Tenofovir Disoproxil Fumarate Tablets Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Tenofovir Disoproxil Fumarate Tablets Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Tenofovir Disoproxil Fumarate Tablets Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Tenofovir Disoproxil Fumarate Tablets Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Tenofovir Disoproxil Fumarate Tablets Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Tenofovir Disoproxil Fumarate Tablets Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Tenofovir Disoproxil Fumarate Tablets Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Tenofovir Disoproxil Fumarate Tablets Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Tenofovir Disoproxil Fumarate Tablets Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Tenofovir Disoproxil Fumarate Tablets Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Tenofovir Disoproxil Fumarate Tablets Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Tenofovir Disoproxil Fumarate Tablets Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Tenofovir Disoproxil Fumarate Tablets Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Tenofovir Disoproxil Fumarate Tablets Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Tenofovir Disoproxil Fumarate Tablets Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Tenofovir Disoproxil Fumarate Tablets Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Tenofovir Disoproxil Fumarate Tablets Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Tenofovir Disoproxil Fumarate Tablets Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Tenofovir Disoproxil Fumarate Tablets Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Aurobindo Pharma
  2. 8.1.1 Aurobindo Pharma Company Information
  3. 8.1.2 Aurobindo Pharma Business Overview
  4. 8.1.3 Aurobindo Pharma Tenofovir Disoproxil Fumarate Tablets Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Aurobindo Pharma Tenofovir Disoproxil Fumarate Tablets Product Portfolio
  6. 8.1.5 Aurobindo Pharma Recent Developments
  7. 8.2 Gilead Sciences
  8. 8.2.1 Gilead Sciences Company Information
  9. 8.2.2 Gilead Sciences Business Overview
  10. 8.2.3 Gilead Sciences Tenofovir Disoproxil Fumarate Tablets Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Gilead Sciences Tenofovir Disoproxil Fumarate Tablets Product Portfolio
  12. 8.2.5 Gilead Sciences Recent Developments
  13. 8.3 GSK
  14. 8.3.1 GSK Company Information
  15. 8.3.2 GSK Business Overview
  16. 8.3.3 GSK Tenofovir Disoproxil Fumarate Tablets Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 GSK Tenofovir Disoproxil Fumarate Tablets Product Portfolio
  18. 8.3.5 GSK Recent Developments
  19. 8.4 Hetero Drugs
  20. 8.4.1 Hetero Drugs Company Information
  21. 8.4.2 Hetero Drugs Business Overview
  22. 8.4.3 Hetero Drugs Tenofovir Disoproxil Fumarate Tablets Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Hetero Drugs Tenofovir Disoproxil Fumarate Tablets Product Portfolio
  24. 8.4.5 Hetero Drugs Recent Developments
  25. 8.5 Strides Pharma
  26. 8.5.1 Strides Pharma Company Information
  27. 8.5.2 Strides Pharma Business Overview
  28. 8.5.3 Strides Pharma Tenofovir Disoproxil Fumarate Tablets Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Strides Pharma Tenofovir Disoproxil Fumarate Tablets Product Portfolio
  30. 8.5.5 Strides Pharma Recent Developments
  31. 8.6 Teva Pharmaceuticals
  32. 8.6.1 Teva Pharmaceuticals Company Information
  33. 8.6.2 Teva Pharmaceuticals Business Overview
  34. 8.6.3 Teva Pharmaceuticals Tenofovir Disoproxil Fumarate Tablets Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Teva Pharmaceuticals Tenofovir Disoproxil Fumarate Tablets Product Portfolio
  36. 8.6.5 Teva Pharmaceuticals Recent Developments
  37. 8.7 Chengdu Beite Pharmaceutical
  38. 8.7.1 Chengdu Beite Pharmaceutical Company Information
  39. 8.7.2 Chengdu Beite Pharmaceutical Business Overview
  40. 8.7.3 Chengdu Beite Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Chengdu Beite Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Product Portfolio
  42. 8.7.5 Chengdu Beite Pharmaceutical Recent Developments
  43. 8.8 Haisco Pharmaceutical
  44. 8.8.1 Haisco Pharmaceutical Company Information
  45. 8.8.2 Haisco Pharmaceutical Business Overview
  46. 8.8.3 Haisco Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Haisco Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Product Portfolio
  48. 8.8.5 Haisco Pharmaceutical Recent Developments
  49. 8.9 Shijiazhuang Lonzeal Pharmaceuticals
  50. 8.9.1 Shijiazhuang Lonzeal Pharmaceuticals Company Information
  51. 8.9.2 Shijiazhuang Lonzeal Pharmaceuticals Business Overview
  52. 8.9.3 Shijiazhuang Lonzeal Pharmaceuticals Tenofovir Disoproxil Fumarate Tablets Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Shijiazhuang Lonzeal Pharmaceuticals Tenofovir Disoproxil Fumarate Tablets Product Portfolio
  54. 8.9.5 Shijiazhuang Lonzeal Pharmaceuticals Recent Developments
  55. 8.10 Luoxin Pharmaceuticals
  56. 8.10.1 Luoxin Pharmaceuticals Company Information
  57. 8.10.2 Luoxin Pharmaceuticals Business Overview
  58. 8.10.3 Luoxin Pharmaceuticals Tenofovir Disoproxil Fumarate Tablets Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Luoxin Pharmaceuticals Tenofovir Disoproxil Fumarate Tablets Product Portfolio
  60. 8.10.5 Luoxin Pharmaceuticals Recent Developments
  61. 8.11 Qilu Pharmaceutical
  62. 8.11.1 Qilu Pharmaceutical Company Information
  63. 8.11.2 Qilu Pharmaceutical Business Overview
  64. 8.11.3 Qilu Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Qilu Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Product Portfolio
  66. 8.11.5 Qilu Pharmaceutical Recent Developments
  67. 8.12 Shanghai Haini Pharmaceutical
  68. 8.12.1 Shanghai Haini Pharmaceutical Company Information
  69. 8.12.2 Shanghai Haini Pharmaceutical Business Overview
  70. 8.12.3 Shanghai Haini Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Shanghai Haini Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Product Portfolio
  72. 8.12.5 Shanghai Haini Pharmaceutical Recent Developments
  73. 8.13 Beijing SL Pharmaceutical
  74. 8.13.1 Beijing SL Pharmaceutical Company Information
  75. 8.13.2 Beijing SL Pharmaceutical Business Overview
  76. 8.13.3 Beijing SL Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Beijing SL Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Product Portfolio
  78. 8.13.5 Beijing SL Pharmaceutical Recent Developments
  79. 8.14 Sichuan Kelun Pharmaceutical
  80. 8.14.1 Sichuan Kelun Pharmaceutical Company Information
  81. 8.14.2 Sichuan Kelun Pharmaceutical Business Overview
  82. 8.14.3 Sichuan Kelun Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Sichuan Kelun Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Product Portfolio
  84. 8.14.5 Sichuan Kelun Pharmaceutical Recent Developments
  85. 8.15 Chongqing Yaoyou Pharmaceutical
  86. 8.15.1 Chongqing Yaoyou Pharmaceutical Company Information
  87. 8.15.2 Chongqing Yaoyou Pharmaceutical Business Overview
  88. 8.15.3 Chongqing Yaoyou Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 Chongqing Yaoyou Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Product Portfolio
  90. 8.15.5 Chongqing Yaoyou Pharmaceutical Recent Developments
  91. 8.16 Zhejiang Sukean Pharmaceutical
  92. 8.16.1 Zhejiang Sukean Pharmaceutical Company Information
  93. 8.16.2 Zhejiang Sukean Pharmaceutical Business Overview
  94. 8.16.3 Zhejiang Sukean Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Zhejiang Sukean Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Product Portfolio
  96. 8.16.5 Zhejiang Sukean Pharmaceutical Recent Developments
  97. 8.17 Chia Tai Tianqing Pharmaceutical
  98. 8.17.1 Chia Tai Tianqing Pharmaceutical Company Information
  99. 8.17.2 Chia Tai Tianqing Pharmaceutical Business Overview
  100. 8.17.3 Chia Tai Tianqing Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 Chia Tai Tianqing Pharmaceutical Tenofovir Disoproxil Fumarate Tablets Product Portfolio
  102. 8.17.5 Chia Tai Tianqing Pharmaceutical Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Tenofovir Disoproxil Fumarate Tablets Value Chain Analysis
  2. 9.1.1 Tenofovir Disoproxil Fumarate Tablets Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Tenofovir Disoproxil Fumarate Tablets Sales Mode & Process
  6. 9.2 Tenofovir Disoproxil Fumarate Tablets Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Tenofovir Disoproxil Fumarate Tablets Distributors
  9. 9.2.3 Tenofovir Disoproxil Fumarate Tablets Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst